Insulin degludec lowers risk of recurrent low blood sugar or has similar risk to insulin glargine

Insulin degludec (Tresiba), a new ultra-long-acting insulin, has a similar or reduced risk of recurrent hypoglycemia— low blood sugar— compared with the commercially available insulin glargine, a new meta-analysis study ...